Skip to main content
Equibles
INTI logo

INTI · Inhibitor Therapeutics, Inc. · Metrics

Track INTI — free

Use INTI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INTI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.11 At close · Oct 16
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been fully executed and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not currently alleviate substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$19.12M
Shares
173.79M
Volume · Oct 16 3900 Avg daily vol (3M) 15.6K

INTI metrics

48 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.11
Market cap
$19.12M

Price action

20 metrics
Price change (1W)
+12.2%
Price change (30D)
+86.4%
Price change (3M)
+41.0%
Price change (6M)
+32.5%
Price change (YTD)
+144.4%
Price change (1Y)
+129.2%
Trailing year
Price change (5Y)
-31.3%
52-week high
$0.12
52-week low
$0.04
Change from 52-week high
-11.3%
Change from 52-week low
+175.0%
Annualized volatility
274.4%
Annualized volatility (3M)
—
Beta
-2.4
RSI (14D)
56.7
Price vs SMA 50
+32.6%
Price vs SMA 200
+69.5%
Avg volume (3M)
15,595
Relative volume
0.3
Average dollar volume
$1,247

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
173.79M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-17.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$3.37M
Net income (TTM)
−$3.31M
Trailing 12 months
Diluted EPS (TTM)
$-0.02
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.02
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.02
Operating cash flow per diluted share (TTM)
$-0.02
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.01
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.01

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-519.1%
Debt / equity
—
Current ratio
3.4
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
3.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$467,930
Latest balance sheet
Cash & equivalents
$515,758
Total assets
$637,190
Total debt
$47,828

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$3.22M
Capital expenditures (TTM)
—
R&D (TTM)
$1.70M
SG&A (TTM)
—
Stock compensation (TTM)
$33,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1042418 CUSIP 45720M105 Visit website Investor relations